# GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
Canonical URL: https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859
Ticker: GSK
Company: GSK plc
Source: GSK plc
Published: 2026-07-28 12:05 EST
Original Source URL: https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/
## Summary

Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia

## Article Body
28 July 2026

Issued: London, UK

For media and investors only

Download (PDF - 142.0KB)

Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia

Catalyst to fuel collaboration and accelerate GSK R&D and medicine development

£400 million investment in UK life sciences

GSK plc (LSE/NYSE: GSK) today announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline. The new 300,000 square foot site, on the Cambridge Biomedical Campus in the heart of the UK’s life sciences “Golden Triangle,” will be home to GSK’s R&D operations in the UK and more than 1,000 GSK scientists.

The Cambridge Biomedical Campus is one of the largest biomedical campuses in Europe. The new location will provide GSK scientists with direct access to a world-class ecosystem of biomedical research, patient care and academia, enabling translational research by bridging laboratory science with clinical practice.

The GSK site will feature state-of-the-art, tech-enabled labs and infrastructure to support research in the company’s focus areas of Oncology, Respiratory, Hepatology, Vaccines and HIV.

The Cambridge Biomedical Campus is home to more than 22,000 people working in life sciences, with more than 37,000 people visiting every day. More than 1 million patients are treated on the campus every year, and over 470 biopharma/ biotech and AI companies are located there. These include many existing GSK partners and collaborations, such as, the Cambridge Centre for Data-Driven Discovery; Cambridge-GSK Translational Immunology Collaboration; Cambridge-GSK Metabolic Science Collaboration; Cambridge Immune Ageing; GSK-Teichmann Lab; and GSK’s Clinical Unit at Addenbrooke’s Hospital.

Luke Miels, Chief Executive Officer, GSK, said: “This investment will accelerate our R&D and help us deliver new, competitive products. It integrates GSK further into one of the world’s leading centres of knowledge and demonstrates the attractiveness of the UK’s life sciences ecosystem.”

Tony Wood, Chief Scientific Officer, GSK, said: “Cambridge has built one of the world’s best life sciences ecosystems, with leading universities, hospitals and biotech companies. The campus provides exceptional opportunities for collaboration. With our existing connections and experience, we see this move as a catalyst for faster, bolder medicines discovery by accelerating the science that matters most for GSK's next wave of medicines.”

The site in Cambridge, currently in development by Prologis, will be part of GSK’s wider UK network of collaboration with leading academic institutions and pioneering scientific organisations, including the University of Oxford, Kings College London, Imperial College, the University of Manchester, Wellcome and the Crick Institute.

As a result of the planned move to Cambridge, GSK will vacate its R&D site at Stevenage, Hertfordshire, with a phased move for employees by 2029. Alongside the move to Cambridge, GSK will also upgrade its existing R&D laboratories at Ware in Hertfordshire and move some employees there to create a fully integrated drug development and commercial manufacturing scale up capability. Overall, the company plans to invest £400 million over 3 years in support of these changes.

GSK will retain its global headquarters in London, which is unaffected by today’s announcement.

GSK invests over £6 billion in R&D every year of which more than £1.5 billion is in the UK.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com .

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q2 Results for 2026.
## Recent Company News
- 2026-07-28 12:05 EST — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859) — Source: GSK plc
- 2026-07-28 12:00 EST — [GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026](https://biopharmsignal.com/news/GSK/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum-plans-ann-1d427d5e) — Source: GSK plc
- 2026-07-28 11:00 EST — [GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China](https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-results-from-a-second-phase-iii--07f96324) — Source: GSK plc
- 2026-07-27 14:55 EST — [ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV](https://biopharmsignal.com/news/GSK/viiv-healthcare-s-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktar-781cde81) — Source: GSK plc
- 2026-07-22 11:21 EST — [Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer](https://biopharmsignal.com/news/GSK/jideytro-zidesamtinib-approved-in-the-us-for-previously-treated-ros1-positive-no-a284b13c) — Source: GSK plc
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)
- 2026-07-28 12:00 EST — UNH — [Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer](https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-fda-clearance-to-initiate-tempo-1-registrationa-5499960d)
- 2026-07-28 12:00 EST — BCLI — [BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman](https://biopharmsignal.com/news/BCLI/brainstorm-appoints-former-fda-associate-commissioner-peter-j-pitts-as-executive-0d7242f8)